Loss of antiphospholipid antibody positivity post-thrombosis in SLE
JournalLupus Science & Medicine
PublisherBMJ Publishing Group
MetadataShow full item record
AbstractBackground/Purpose Loss of positivity of antiphospholipid antibodies has been observed in clinical practice post-thrombosis in patients with SLE with secondary antiphospholipid syndrome (APS). Our study defined the frequency of this loss and the duration before positivity recurred. Methods In this prospective study, patients with SLE having at least two positive antiphospholipid markers prior to thrombosis and at least 1 year of follow-up after thrombosis were included. Antiphospholipid markers included lupus anticoagulant (dilute Russell viper venom test >45 s followed by mixing and confirmatory tests) and/or anticardiolipin titre (aCL IgG ≥20, aCL IgM ≥20 and/or aCL IgA ≥20). The percentage of visits with positive antiphospholipid markers after thrombosis was calculated. For patients with a negative antiphospholipid marker any time after thrombosis, survival estimates were performed to calculate the time to return of antiphospholipid positivity. Results In APS due to SLE, complete loss of antiphospholipid positivity post-thrombosis was up to 41% for aCL IgG, 51% for IgM and 50% for IgA, but only 20% for those with lupus anticoagulant. Of those who at some point lost aCL IgG or became negative for lupus anticoagulant, the majority (60% and 76%, respectively) reacquired the antibody within 5 years. In contrast, of those who lost aCL IgM or IgA, fewer reacquired it within 5 years (37% and 17%, respectively). Conclusion Intermittent positivity of antiphospholipid antibodies is present in APS due to SLE. These fluctuations make it difficult to decide on length of anticoagulation. Lupus anticoagulant is more likely to persist post-thrombosis.
Rights/Terms© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/13941
- The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus.
- Authors: Bertolaccini ML, Atsumi T, Escudero Contreras A, Khamashta MA, Hughes GR
- Issue date: 2001 Dec
- Anti-beta2-glycoprotein I: prevalence, clinical correlations, and importance of persistent positivity in patients with antiphospholipid syndrome and systemic lupus erythematosus.
- Authors: Danowski A, Kickler TS, Petri M
- Issue date: 2006 Sep
- Clinical manifestations and antiphosphatidylserine antibodies in patients with systemic lupus erythematosus: is there an association?
- Authors: Sahin M, Duzgun N, Tunc SE, Tutkak H
- Issue date: 2007 Feb
- Utility of antiphosphatidylserine/prothrombin and IgA antiphospholipid assays in systemic lupus erythematosus.
- Authors: Akhter E, Shums Z, Norman GL, Binder W, Fang H, Petri M
- Issue date: 2013 Mar
- Antiphospholipid antibodies in paediatric systemic lupus erythematosus, juvenile chronic arthritis and overlap syndromes: SLE patients with both lupus anticoagulant and high-titre anticardiolipin antibodies are at risk for clinical manifestations related to the antiphospholipid syndrome.
- Authors: Gattorno M, Buoncompagni A, Molinari AC, Barbano GC, Morreale G, Stalla F, Picco P, Mori PG, Pistoia V
- Issue date: 1995 Sep